Ketamine-Assisted Psychotherapy (KAP)
Ketamine-Assisted Psychotherapy (KAP) is a psychedelic-assisted approach that emerged in clinical practice around 2010 rather than from a single manual, with Phil Wolfson and Raquel Bennett among the clinicians who defined its protocols. Its core mechanism: ketamine's dissociative state, and the plasticity that follows it, are treated as a window for psychotherapeutic processing and new learning; the window is proposed rather than demonstrated. This catalogue links it to depression, PTSD and chronic pain, typically in individual format, short-medium.
Related condition topics
These links support exploration. They do not establish that KAP is effective or recommended for each condition.
How Ketamine-Assisted Psychotherapy works
Ketamine's dissociative state, and the plasticity that follows it, are treated as a window for psychotherapeutic processing and new learning; the window is proposed rather than demonstrated
Ontology
Treatment-resistant conditions involve rigid neural patterns; ketamine disrupts rigidity and opens plasticity window
Therapeutic Voice
"Last week you kept coming back to 'none of it is solid.' Let's stay there. What have you been treating as solid?"
View of the Person
A consciousness capable of radical state-shifts that open windows for reorganization of rigid patterns
Epistemology
Evidence
7 source checks available
An overall effectiveness assessment has not been completed. This describes the state of our review, not whether the approach works.
Guidelines and official sources (7)
6 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- SPRAVATO (esketamine) original prescribing information
Not a treatment recommendation
The historical drug indication is verified. It does not establish approval or guideline endorsement of KAP. This original label is not current prescribing information.
Scope: Esketamine nasal spray plus an oral antidepressant for adult TRD in 2019
- Management of Major Depressive Disorder
Discussed in the source
VA/DoD weakly suggests ketamine or esketamine augmentation. The recommendation concerns medication, not a named KAP psychotherapy protocol.
Scope: MDD after several adequate pharmacological trials have failed
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Discussed in the source
VA/DoD weakly recommends against ketamine for PTSD. The statement concerns medication and does not separately evaluate KAP.
Scope: Ketamine pharmacotherapy for adult PTSD; not a separate KAP psychotherapy assessment.
- Assessment and Management of Patients at Risk for Suicide
Discussed in the source
VA/DoD weakly supports ketamine infusion for short-term ideation reduction; evidence for preventing attempts or suicide is insufficient. KAP is not separately recommended.
Scope: Adjunctive ketamine infusion in adults aged 18 and over with major depression and suicidal ideation; medication rather than KAP psychotherapy.
- Management of Major Depressive Disorder
Discussed in the source
VA/DoD suggests against ketamine/esketamine as initial pharmacotherapy (weak against). Its separate augmentation recommendation concerns prior treatment failure; neither recommendation endorses a named KAP psychotherapy protocol.
Scope: Adults choosing initial medication treatment for MDD.
- Management of Bipolar Disorder
Discussed in the source
VA/DoD finds insufficient evidence for ketamine/esketamine alone or as adjuncts. The recommendation concerns medication and does not endorse KAP psychotherapy.
Scope: Adults with acute bipolar depression.
- Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults
Discussed in the source
APA reports insufficient evidence for ketamine in these comparisons. This is a drug-level finding, not a separate evaluation of the KAP psychotherapy protocol.
Scope: Adults with PTSD; ketamine compared with an active or inactive intervention.
Recorded material under review
The existing notes below are retained separately from assessment records. These recorded claims await source checking, including study design, recommendations and numerical estimates.
Multiple RCTs of ketamine for depression; fewer of KAP specifically
Kishimoto et al. (2016) meta-analysis
Ketamine has strong pharmacological evidence. KAP (therapy + ketamine integration) has fewer controlled studies specifically.
Training and certification
Licensed mental health professional or prescriber. KAP requires a therapeutic triangle (therapist + prescribing physician + patient), so training paths differ for therapists vs. prescribers. No single governing body: multiple established training organizations exist, cross-recognizing each other's foundational modules. KRIYA Institute (kriyainstitute.com) maintains a curated directory of training programs.
No single certifying body. Certificates available from established programs including: Fluence (fluencetraining.com): Professional Certificate in KAP via Essentials prerequisite + 12-week specialty course, CE credits available; Polaris Insight Center (polarisinsight.com): modular program (Modules 1–5 + Practice Module, 8 CE hrs each, $350–375/module) plus 5-day experiential retreats and 1–2 year certificate pathway; PRATI (pratigroup.org): Fort Collins, CO; Alchemy Community Therapy Center (alchemytherapy.org): Oakland, CA; Ketamine Training Center (theketaminetrainingcenter.com): founded by Phil Wolfson, includes Dharma K experiential retreats. Polaris cross-accepts Module 1 from PRATI, KTC, KRIYA, and Sage.
Varies by program. Fluence: Essentials + 12-week specialty. Polaris: foundational series (6 modules, ~48 CE hrs) + advanced/special topics + experiential retreats; full cohort pathway is 52 hrs over 5 months. Full certificate programs: 1–2 years including consultation.
Polaris modules: $325–375 each (+ $79 for CEs); full cohort: inquire; experiential retreats additional. Fluence: Essentials + KAP specialty bundle (inquire for current pricing, intro bundle $375). Consultation fees typically $75–150/session across programs.
Find a trained therapist
Equity & Cultural Adaptations
Clinical cautions and blind spots
Assessment and precautions
Active psychosis or psychotic spectrum disorders, uncontrolled hypertension, pregnancy, history of intracranial hypertension, severe dissociative disorders, active substance use disorder, untreated bipolar disorder
Blind spots
Regulatory fragmentation; limited standardization of psychotherapy component; risk of ketamine becoming the treatment rather than catalyst
Philosophical roots
James (varieties of religious experience: altered states as data); Grof (non-ordinary states); Wolfson (ketamine as psychedelic medicine rather than anesthetic adjunct); neuroplasticity research
Compared with other approaches
Controversies
The therapy half is the least standardized and least regulated part: 'KAP' covers everything from a trained dyad running preparation and integration to a clinic that monitors vitals while the client wears an eye mask. Off-label prescribing, at-home protocols, and fast commercial growth have outrun both the evidence and the rules.
Ketamine’s off-label psychiatric use operates in a regulatory gray area: no FDA approval for KAP specifically (only Spravato/esketamine for treatment-resistant depression via REMS), wide variation in dosing protocols, minimal standardization of the psychotherapy component, and concerns about clinics prioritizing volume over integration. The at-home ketamine telehealth model (Mindbloom, Joyous, etc.) has drawn particular scrutiny for minimal clinical oversight.
KAP practitioners argue off-label use is standard medical practice and that the psychotherapy component is what differentiates KAP from ketamine infusion clinics. Journey Clinical and similar platforms attempt to standardize the integration model.
Matthew Perry’s death in October 2023 from acute ketamine effects brought mainstream attention to ketamine overprescription. Subsequent reporting revealed a loosely regulated ecosystem of telehealth ketamine prescribers with minimal psychiatric evaluation. Multiple providers have faced scrutiny for prescribing without adequate screening.
The field has drawn distinctions between KAP (therapist-guided, integration-focused) and ketamine prescribing mills. Some practitioners have called for clearer regulatory frameworks to protect both the medicine and patients.
KAP in 1 Comparative Clinical Vignette
Each vignette presents the same client through multiple theoretical lenses side by side — showing how KAP formulates presenting problems, sets treatment focus, and sounds in the consulting room compared with other approaches. This comparative pedagogy is unique to Epoché Clinical; no other clinical reference systematically formulates the same case across traditions.
Test Yourself
Three phases of KAP?
Show answer
Preparation, Medicine session, Integration.